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Prostate cancer is the fourth most commonly 
diagnosed cancer in the world as well as the second 
most commonly occurring cancer in men with 
1,276,106 new cases in 2018 representing 7.1% of 
all newly diagnosed cancer cases [1].
The widespread population screening through 
the determination of prostate-specific androgen 
(PSA) levels in the male population has led to 
AbstrAct
background: about 5% of prostate cancer cases are metastatic at diagnoses. radiotherapy of both primary tumor and sec-
ondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients.
Materials and methods: patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively 
reviewed. all patients received moderate hypofractionated IMrT/VMaT up to 63 Gy in 21 daily fractions of 3 Gy to prostate 
and metastases with neoadjuvant and concurrent androgen deprivation therapy (aDT). according to known advances some 
patients also received abiraterone, enzalutamide, or docetaxel.
results: Between 2015–2020, we attended 26 prostate cancer patients (median age 69.5 years, range 52–84) with simultane-
ous oligometastases [mean 2.1 metastases, median 1.5 metastases (range 1–6)]. eighteen patients (69%) presented lymph 
node metastases, 4 (15.5%) bone metastases and 4 (15.5%) both lymph node and bone metastases. With a median follow-up 
of 15.5 months (range 3–65 months), 16 patients (62%) are alive and tumor free while 10 (38%) are alive with tumor. Four pa-
tients (17%) developed tumor progression, out of irradiated area in all cases, with a median time to progression of 43.5 months 
(range 27–56 months). actuarial progression-free survival (pFs) rates at 12 and 24 months were 94.1% and 84.7%, respectively. 
No grade > 2 acute or late complications were recorded.
conclusions: simultaneous directed radical hypofractionated radiation therapy for prostate and metastases is feasible, well 
tolerated and achieves an acceptable pFs rate. however, further studies with longer follow-up are necessary to definitively 
address these observations. 
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a constant increase in the number of diagnoses 
of early-stage prostate cancer and a reduction in 
patients with de novo metastatic prostate cancer, 
which is assumed, according to the findings of the 
large PSA European Randomized Study of Screen-
ing for Prostate Cancer (ERSPC) trial, to be less 
than 5% of the total of newly diagnosed cases [2].
Although the presence of de novo metastasis pre-
sumes a more advanced stage of cancer, and a worse 
prognosis compared to the development of meta-
chronous metastases, in the last decades the concept 
of oligometastatic disease has strongly emerged [3]. 
Defined for the first time in 1995 by Hellman and 
Weichselbaum as an intermediate stage between ex-
clusively local and widely disseminated disease [4], the 
oligometastatic state is characterized by the presence 
of a limited number of metastases (≤ 5 metastases) in 
a limited number of organs. Those patients could ben-
efit in terms of survival of aggressive local treatments 
of the oligometastatic disease. Advances in diagnostic 
imaging techniques, with the generalization of the 
use of MRl or PET-CT with tracers with greater spe-
cificity for prostate cancer such as choline, fluciclovine 
and the prostate-specific membrane antigen (PSMA) 
cause an increase in the diagnosis of oligometastatic 
disease from the first moment of diagnosis, favoring 
the adoption of specifically targeted treatments [5].
Systemic treatment with androgen blockade, 
sometimes combined with chemotherapy based 
on docetaxel, has been traditionally considered the 
gold standard in de novo metastatic prostate cancer. 
However, the increase in the diagnosis of patients 
with limited oligometastatic involvement leads to 
an increasing shift towards a more aggressive treat-
ment and considering the option of performing 
a curative therapeutic approach to local disease and 
oligometastases [6].
The objective of our analysis in this paper is to 
retrospectively review our experience regarding ef-
ficacy and tolerance of a curative approach to de 
novo oligometastatic prostate cancer by using ra-
diotherapy on the primary location of the tumor 
and on oligometases limited to patients with loco-
regional lymph node disease and / or extra-pelvic 
lymph node or bone metastases.
Materials and methods
We have retrospectively reviewed and analyzed 
all the patients who were treated in our department 
between January 2015 and August 2020 with the 
diagnosis of de novo oligometastatic prostate ad-
enocarcinoma. Inclusion criteria comprised loco-
regional or distant lymph node metastases and/or 
bone metastases without any other limitation in the 
number beyond the possibility of performing radia-
tion therapy with radical intention on the primitive 
tumor and metastatic sites. We limited the analysis 
to patients with lymph node and / or bone metas-
tases as proposed in other clinical trials included in 
the discussion and excluded the presence of simul-
taneous visceral metastases without limiting the 
radical intention to treat the prostate and metastas-
es-directed therapy (MDT) by the number of meta-
static sites provided that the patients’ conditions 
and treatment characteristics allowed it. Diagnosis 
of metastatic involvement outside the prostate was 
made mostly using positron emission tomography 
(PET) with choline as a tracer, pelvic magnetic res-
onance imaging (MRI), computerized tomography 
(CT) or bone scan, in order of frequency.
radiation therapy
All included patients were treated with a moder-
ate hypofractionated radiotherapy schedule com-
prising 21 daily fractions of 3 Gy up to a total dose 
of 63 Gy over 4.2 weeks (EQD2Gy for a/b = 1.5 of 
81 Gy) on the prostate and metastatic sites concur-
rently with whole pelvic nodal irradiation in 21 
fractions of 2.2 Gy up to 46.2 Gy (EQD2Gy for 
a/b = 1.5 of 48.8 Gy).  
The patients were immobilized in a supine posi-
tion using knee and heel supports. The patients’ 
previous preparation for the planning CT included 
fasting for at least 8 hours prior to the administra-
tion of intravenous contrast, use of prior laxatives 
for rectal emptying and comfortably full bladder 
with bladder contrast. Axial images were obtained 
at 3 mm intervals through the prostate with a heli-
cal scanner. A CTV_p (CTV prostate) was defined 
as the entire prostate, seminal vesicles and areas 
suspected of harboring extra-prostatic extension of 
the tumor. A non-uniform PTV_p (PTV prostate) 
was created by expanding the CTV_p by 5 mm in 
all directions, except the posterior aspect where it 
was expanded by only 3 mm with the intention of 
reducing the risk of irradiation of the anterior wall 
of the rectum. A CTV_en (CTV elective nodes) 
including pelvic lymph nodes was defined in all 
patientsfrom the bifurcation of the iliac vessels and 
Angel Montero et al. radical radiotherapy for de novo oligometastatic prostate carcinoma
607https://journals.viamedica.pl/rpor
following their trajectory by adding a 7 mm margin 
to encompass the distal common iliac nodes, pre-
sacral lymph nodes (S1–S3), external iliac lymph 
nodes, internal iliac lymph nodes, and obturator 
lymph node, excluding areas of overlapping with 
the bowel, bladder or bone. A margin of 5 mm was 
added to CTV_en to create PTV_en (PTV elective 
nodes) of pelvic lymph nodes. The definition of the 
areas of lymph node or bone oligometastasis was 
performed by fusion of the planning CT with the 
diagnostic PET-Choline or MR images. A third, or 
successive, CTV were created for the oligometa-
static lesions (CTV_om) by adding 5 mm to make 
the corresponding PTV for oligometastatic lesions 
(PTV_om). The bladder, rectum, small bowel, 
cauda equine, femoral heads and penile bulb were 
contoured as organs at risk (OAR) in all patients. 
RayStation (RaySearch Laboratories, Stockholm, 
Sweden) planning treatment system was used to 
generate dynamic multileaf collimator plans. All 
patients were treated with highly conformal radio-
therapy techniques, either through the use of mul-
tiple fields conformed with the intensity modulated 
radiotherapy (IMRT) technique or with multiple 
coplanar arches with the volumetric modulated arc 
therapy (VMAT) technique indistinctly and at the 
discretion of a medical physicist. Treatment plan-
ning goals and dosimetric constraints are detailed 
in Table 1.
Patients were treated 5 days per week. Daily 
verification by using LINAC cone-beam CT was 
performed together with Catalyst SIGRT (Sur-
face image guided radiotherapy system of C-Rad, 
Stockholm, Sweden) for intrafraction patient mo-
tion management or Clarity-4D Monitoring sys-
tem (Elekta AB, Stockholm, Sweden) for advanced 
intra-fraction motion management of the prostate 
and surrounding OAR. All patients were premedi-
cated with alpha-adrenergic antagonists from the 
time of the planning CT scan, during radiotherapy 
and for at least one month after the end of the ir-
radiation. 
hormonal and systemic therapy
All patients underwent complete hormonal 
blockade using antiandrogens and gonadotro-
pin-releasing hormone (GnRH) analogues. Pa-
tients received neoadjuvant and concurrent irra-
diation androgen deprivation therapy (ADT) and 
maintained later until a minimum of 24 months or 
until progression of the disease, according to the 
preferences of the treating physician. Depending 
on the evolution of the clinical trials throughout 
the study period, treatments with docetaxel or 
abiraterone and prednisone were also authorized 
following a multidisciplinary decision of the Tu-
mor Board.
evaluation and statistics
Follow-up length was estimated from the mo-
ment of initiation of first treatment (systemic treat-
ments or radiotherapy), until the date of death or 
last follow-up. Evaluation of patient status was 
made according to clinical exams and available im-
age tests, including CT, bone scintigraphy, MRI, 
PET choline. Local control (LC) was defined as the 
absence of relapse or evident progression in the 
irradiated volumes, both in the primary prostate 
and in the treated oligometastases. Distant metas-
tasis-free survival (DMFS) was defined by the ab-
sence of new metastatic sites different from those 
initially treated. Finally, progression-free survival 
(PFS) was defined as the period free of local failure 
and/or the appearance of new distant metastases. 
Biochemical relapse-free survival (bRFS) was not 
table 1. Treatment planning and dosimetric constraints 
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cauda equina Dmax < 53 Gy
penilebulb Dmean < 42.6 Gy
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considered an assessable item since it could be in-
fluenced by ADT in all patients.
The Kaplan-Meier statistical analysis was used 
for the actuarial calculations using the log-rank 
test for the comparisons made between the survival 
curves and the Chi-square analysis for all those 
comparisons made between groups and statistical 
significance was considered to be  obtained when 
reaching p < 0.05. The SPSS [IBM SPSS Statistics 
for Windows, Version 19.0. (Armonk, NY: IBM 
Corp.)] package software was used for all calcula-
tions.  
The CTCAE v5.0 scale was used to evaluate ad-
verse effects. Acute toxicity was defined as those 
complications that appeared between the end of 
treatment and for 3 months afterwards, while side 
effects observed from 3 months to the date of the 
last follow-up were considered as late toxicity. Pa-
tients were evaluated weekly during EBRT, then 
monthly until month 3 and at 3- to 6-month inter-
vals thereafter. 
results
Between February 2015 and July 2020, 26 men 
at a median age of 69.5 years (range 52–84 years) 
were referred with a diagnosis of prostate adeno-
carcinoma with a synchronous presence of lymph 
node or bone metastases and with an average and 
median PSA values of 32.5 ng/mL and 113 ng/mL 
(range 2.6–295) respectively. Three patients (12%) 
had Gleason ≤ 6, 8 (31%) Gleason 7, 7 (27%) Glea-
son 8 and 8 (31%) Gleason ≥ 9. Eighteen patients 
(69%) presented exclusively lymph node metasta-
ses, 4 (15.5%) bone metastases and 4 (15.5%) both 
lymph node and bone metastases simultaneously. 
Twenty-six per cent of the lymphatic metastases 
were located in the obturator nodes and 19% in 
the common iliac, external iliac and internal iliac 
nodes, respectively. The bone metastases settled 
mainly on the pelvic girdle, 30% in the sacroiliac 
region. Only in one case was bone metastasis ob-
served in the spine outside the pelvis. Table 2 sum-
marizes the complete characteristics of the series 
analyzed and Figure 1 shows the locations of me-
tastases and their relative frequency.
Hormonal treatment with antiandrogens and go-
nadotropin releasing hormone (GnRH) analogues 
was prescribed as neoadjuvant therapy in 23 men 
(88%), with a median of 4 months (range 1–14) be-
fore radical intention radiotherapy of the primary 
tumor and oligometastatic localizations, and in 3 
patients (12%) coinciding with the start of radiation 
therapy. In addition to ADT, 2 patients received 6 
cycles of docetaxel and other 3 patients received 
abiraterone and prednisone at the time of diagnosis 
and continued with the treatment on last follow-up, 
having maintained systemic treatment for 12, 21 
and 22 months, respectively.
With a median follow-up of 15.5 months (range 
3–65 months), 16 patients (62%) are alive with-
out evidence of local or distant relapse or progres-
sion while 10 (38%) are alive with local or distant 
tumor progression according to clinical and im-
age performed exams. No patient has died during 
follow-up from cancer or of any other cause. Four 
patients (17%) have developed tumor progression 
in different locations during follow-up with a me-
dian time to progression of 43.5 months (range 
table 2. patients’ characteristics
N = 26 N (%)
age: median (range) 69.5 (52-84)
PsA
average 32.5 ng/mL
Median (range) 13 (2.6-295) ng/mL
Grade group (Gleason score)
1 (≤ 6) 3 (12)
2 (3 + 4) 4 (15)
3 (4 + 3) 4 (15)
4 (8) 7 (27)















Lymph and bone 4 (15)
psa — prostate-specific androgen
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27–56 months): lymph node metastases outside 
the pelvis in 2 patients, vertebral bone metasta-
ses in 2 patients, bone metastases in the iliac bone 
in one patient and pulmonary metastases in 1 pa-
tient. It should be noted that no recurrence during 
follow-up was observed in a previously irradiated 
area. In the 3 patients who presented lymph node 
and/or bone metastases, salvage radiotherapy was 
considered, administering doses of 25 Gy in 5 frac-
tions on retroperitoneal lymph nodes with simul-
taneous boost up to 35 Gy in 5 fractions on macro-
scopically involved lymph nodes, a dose of 18 Gy in 
a single fraction on vertebral metastases and a dose 
of 35 Gy in 5 fractions in iliac bone metastases. Of 
these 4 patients with metastatic tumor progression, 
2 restarted hormonal blockade with antiandrogen 
and LHRH analog while one patient received abi-
raterone and prednisone and, subsequently, caba-
zitaxel in the face of new lung progression, which 
they maintained until the date of the last follow-up. 
With a median time of 7 months (range 3–23) from 
the second irradiation, 2 patients are alive with pro-
gressing tumor and 2 patients are alive with no 
evidence of relapse or progression. We have not 
observed any case of resistance to castration, most 
likely due to the short follow-up period, which is 
why bRFS could not be adequately evaluated. The 
actuarial PFS rates at 12 and 24 months were 94.1% 
and 84.7%, respectively (Fig. 2). Univariate analysis 
performed included age, PSA value at diagnoses, 
tumor stage, number and location of oligometas-
tases, Gleason group grade classification and use of 





Figure 1. Number and location of de novo oligometastases in lymph nodes (circle) and bone (square)
Figure 2. Dose distribution of simultaneous irradiation 
of prostate (1), bone metastases (2) and lymph node 
metastases (3)
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different systemic treatments. None of these factors 
studied in the univariate showed statistical signifi-
cance.
Tolerance to treatment was acceptable. We did 
not observe cases of acute or late G3 or higher 
genitourinary or gastrointestinal toxicity. Fifteen 
patients (58%) presented acute genitourinary tox-
icity, 14 G1 and 1 G2, and 1 patient (4%) late G1 
genitourinary toxicity. Seven patients (27%) had 
acute gastrointestinal toxicity of G1 in all cases and 
1 patient (4%) had late G2 gastrointestinal compli-
cations (Tab. 3). Although the toxicity associated 
with hormonal treatment was not the objective of 
our study, we reviewed it without observing serious 
secondary complications, sexual dysfunction being 
the most relevant of them. Given the low relative 
number of patients on abiraterone, we are also un-
able to draw conclusions about related toxicity.
Discussion
Since Hellman and Weichselbaum defined the 
existence of an intermediate state between local-
ized tumor and generalized metastatic disease, 
which they called an oligometastatic state, suggest-
ing that these patients could have a more favorable 
behavior with better disease-free intervals and even 
longer survival, there has been a great interest in 
trying to identify more precisely these oligometa-
static patients susceptible to more effective treat-
ment [4]. The increasing use of more sensitive and 
precise diagnostic imaging tests, such as PET-cho-
line, F18-fluciclovine PET or the most promising 
PET-PSMA, favors early identification of patients 
with oligometastatic prostate cancer at the time of 
first diagnosis (de novo oligometastatic prostate 
carcinoma) [7, 8].
The prognosis of de novo metastatic prostate 
adenocarcinoma seems to be directly related both 
to the tumor burden, referring to the number of 
metastatic sites, and to their anatomical location. 
The analysis by Gandaglia et al., performed on 
3,587 men with de novo metastatic prostate cancer 
included in the SEER database, showed that the 
presence of visceral metastases represented a nega-
tive prognostic factor associated with significantly 
lower median overall and cause-specific survival 
than those patients with exclusively bone or lymph 
node metastases, the latter showing higher median 
survival rates [9]. Similarly, Halabi et al. published 
results of a meta-analysis including 9 phase III clin-
ical studies with a total of 8,820 patients, observing 
that the presence of visceral liver or lung metasta-
ses is associated with a significantly worse survival 
compared to patients exclusively with lymph node 
and/or bone metastases [10].
The treatment of metastatic hormone-sensitive 
prostate cancer is a considerable challenge. In re-
cent years, there has been a remarkable evolution, 
from the first studies that limited treatment to the 
administration of systemic hormonal treatment 
exclusively assuming that with a primitive tumor 
being widespread the importance of local treat-
ment should be of less importance, until the most 
recent results of different randomized studies that 
have demonstrated the importance of prostate lo-
cal treatment. The benefit of local treatment trans-
lates into improvements not only in biochemical 
relapse-free survival, but also in overall survival 
and cause-specific survival, especially in patients 
with low metastatic tumor burden. The HORRAD 
study that analyzed the impact of adding radiother-
apy to hormonal treatment in patients with initial 
metastatic bone disease did not observe differences 
table 3. acute and late toxicities 












GIT — gastrointestinal toxicity; GUT — genitourinary toxicity; G — grade
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between the 2 arms of the study, although the con-
fidence interval (CI) cannot exclude a substantial 
survival benefit [11]. In the same way, the STAM-
PEDE study, although it did not find differences 
when radiotherapy to the primary tumor was added 
to systemic treatment, used the results in a prespec-
ified subgroup analysis by metastatic burden and 
showed a significant benefit with radiotherapy with 
respect to failure-free survival, progression-free 
survival, cancer-specific survival and overall sur-
vival in patients with a low metastatic burden [12]. 
Further analysis by STAMPEDE also suggests that 
the benefit of radiotherapy would also extend to 
patients who present with de novo exclusive meta-
static lymph node disease without the presence of 
bone or visceral metastases [13]. In the context of 
de novo disseminated tumor with a “low meta-
static burden”, local treatment is justified both in 
reducing the tumor burden, which can prevent the 
seeding of new metastases from both the primary 
and secondary lesions, as in the possible induc-
tion of systemic, abscopal effects, through immune 
activation induced by irradiation of tumor areas 
[14, 15]. Defining what is meant by “low metastatic 
burden” is a challenge yet to be tackled. Differ-
ent studies have used different criteria to establish 
the low-risk group. The HORRAD study suggested 
a benefit, although not statistically significant, in 
patients considered “low-volume metastatic” char-
acterized by the presence of less than 5 bone me-
tastases, PSA < 142 ng/mL, and Gleason ≤ 8 [11]. 
Meanwhile, the STAMPEDE study applied the cri-
teria defined by the CHAARTED trial to identify 
as “high metastatic burden” the existence of 4 or 
more bone metastases, at least one of them being 
outside the pelvis or spine, or the presence of vis-
ceral metastases to define the subgroup of patients 
benefiting from radiation therapy to the primary 
prostate tumor [12, 16]. A recent systematic review 
and meta-analysis of the HORRAD, STAMPEDE 
and the ongoing PEACE1 studies including a total 
of 2,126 men with de novo oligometastatic prostate 
cancer, demonstrated an increase in 3-year over-
all survival when adding radiation therapy to the 
prostate in patients with less than 5 bone metastases 
[17]. However, despite the observed survival gain, 
two aspects that appear relevant in the context of 
de novo oligometastatic prostate cancer patients 
should be highlighted. First, the doses of radio-
therapy administered can be considered “low” in all 
3 studies, lower than those currently recommended 
for the local treatment of prostate cancer. Assum-
ing an alpha/beta value of 1.5 Gy for prostate can-
cer, the biologically effective dose (BED1.5Gy) from 
the three studies would be as follows: 163.3–171 
Gy (HORRAD), 155.8–180 Gy (STAMPEDE) and 
172.7 Gy (PEACE1). It has long been known that 
moderate dose-escalation in prostate cancer radia-
tion therapy above a BED1.5Gy of 180 Gy is associated 
with increased tumor control [19]. Our patients re-
ceived a prescription of 63 Gy in 21 daily fractions, 
over 4.2 weeks, with a BED1.5Gy  of 189 Gy both to 
the primary and metastatic lesions; a dose higher 
than those administered in the HORRAD, STAM-
PEDE, and PEACE1 trials. On the other hand, none 
of the 3 mentioned studies contemplated the op-
tion of treatment directed specifically to distant me-
tastases. The systemic approach is considered the 
standard treatment for metastatic prostate cancer, 
with the addition of local treatment of the prostate 
in selected cases. Main goal of treating metastatic 
disease has traditionally been to alleviate the symp-
toms that metastases may cause. However, more 
recently, the concept of metastasis-directed treat-
ment (MDT) has emerged with force for selected 
groups of patients. The STOMP (Surveillance or 
Metastasis-directed Therapy for Oligometastatic 
Prostate Cancer Recurrence) trial randomized 62 
patients with oligorecurrent hormone-sensitive 
prostate cancer with up to 3 metastases to sur-
veillance or metastasis-directed therapy (MDT) by 
surgery or SBRT. The 3-year results demonstrated 
the benefit of MDT in the primary endpoint of 
androgen deprivation therapy (ADT) free survival, 
maintaining the same quality of life in both groups 
of patients [19]. In 2020, the authors updated their 
5-year data confirming 34% ADT-free survival in 
the MDT-randomized arm compared to 8% in the 
observation arm, and these results were indepen-
dent of the location of metastases or of the speed of 
disease progression [20]. The ORIOLE (Observa-
tion vs Stereotactic Ablative Radiation for Oligo-
metastatic Prostate Cancer) trial randomized 54 
men with hormone-sensitive prostate cancer with 
1–3 oligometastases to receive MDT with SBRT 
versus observation. With a median follow-up of 
19 months, the primary goal of 6-month progres-
sion-free survival was 39% in the observation arm 
versus 81% in the MDT arm (p = 0.005) with no 
grade 3 or higher observed complications [21]. Fi-
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nally, the PEACE V-STORM (Salvage Treatment of 
OligoRecurrent nodal prostate cancer Metastases) 
trial aims to analyze the impact of adding elective 
pelvic lymph node irradiation to the MDT of pelvic 
lymph node oligorrecurrences, planning to com-
plete the study by the end of 2023 [22].
All patients included in our analysis received 
local treatment with radical intention on the pri-
mary tumor as well as metastasis-directed ablative 
radiotherapy on affected lymph nodes and bone 
metastases. Radiation therapy with ablative intent 
to both the primitive prostate tumor and the dif-
ferent metastatic sites could be an alternative with 
a curative intent to be evaluated in the context of 
the multidisciplinary approach to de novo oligo-
metastatic prostate cancer. However, a limited 
number of studies have focused on developing this 
option. Table  4 summarizes the results observed 
by 5 groups that propose radiotherapy with a cu-
rative intent both of the primitive prostate tumor 
and of the metastatic sites in patients with de novo 
oligometastatic hormone-sensitive prostate cancer 
[23–27]. All included studies are retrospective and 
show some appreciable differences. First, there is 
no clear uniformity, beyond excluding the pres-
ence of visceral metastases, to identify the oligo-
metastatic status for radical prostate treatment and 
MDT: Imber et al. include up to 6 metastases [26], 
Tsumura et al. up to 5 [24], Reverberi et al. less 
than 5 [25], while Deantoni et al. limit the inclu-
sion to a maximum of 2 bone metastases [27] and 
Cho et al. do not specify this aspect [23]. Second, 
there are notable variations in irradiation schemes, 
fractionations, and total doses administered to 
both prostate tumors and oligometastases. To fa-
cilitate comparison, the BED1.5Gy of the different 
regimens has been calculated. The BED1.5Gy values 
administered to the prostate vary between 160–318 
Gy while for MDT they vary between 70–156 Gy. 
Coincidence exists regarding the simultaneous use 
of ADT in all patients, although the use of other 
systemic treatments, such as abiraterone, enzaluta-
mide or docetaxel shows great variations between 
the different studies. Finally, there is a coincidence 
in the acceptable tolerance of the treatments,  with 
rare occurrence of acute and late genitourinary or 
gastrointestinal toxicity equal to or greater than 
grade 3. Our results compare well with those re-
ported by other groups, although the duration of 
follow-up is somewhat shorter.
We are aware of some strengths and weaknesses 
of our study. All patients received identical hypo-
fractionated radiation treatment, with doses that 
can be considered high both on the prostate and on 
MDT and similar to those used for curative radical 
radiotherapy in patients with localized non-meta-
static prostate cancer. We are also aware that one 
of the main criticisms of our work is that, strictly 
speaking, the consideration of the presence of pel-
vic lymph node metastases as oligometastasis can 
be discussed. However, it is a common practice in 
other studies on the treatment of oligometastatic 
prostate cancer [20, 21, 24, 25]. Also, all included 
patients were on ADT, which could contribute to 
making an exact and consistent evaluation of treat-
ment response difficult. Likewise, the low number 
of patients, the short follow-up and the retrospec-
tive nature of this study oblige us to be cautious 
with these results and to wait for longer follow-up.
conclusion
The increasing precision and accuracy of imag-
ing tools is leading to an increase in the de novo 
diagnosis of prostate carcinoma with the simulta-
neous presence of a low number of metastases (oli-
gometastasis), and represents a challenge for those 
involved in the treatment of these patients. The pos-
sibility of performing radical radiation therapy with 
moderate hypofractionation for curative intent of 
both primary prostate tumor and metastatic sites is 
a real option for selected patients with good rates of 
tumor control with acceptable tolerance. However, 
more randomized studies with greater recruitment 
and follow-up are still required to confirm these 
good results.
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